Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
87°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hemogenyx Pharmaceuticals Plc.
(OP:
HOPHF
)
0.0031
UNCHANGED
Last Price
Updated: 12:21 PM EDT, Aug 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0031
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0031
Today's Range
0.0031 - 0.0031
52wk Range
0.0031 - 0.0400
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
September 08, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
September 01, 2024
Via
ACCESSWIRE
Performance
YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
-92.25%
-92.25%
6 Month
-92.25%
-92.25%
1 Year
N/A
N/A
More News
Read More
Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference
August 27, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation
July 28, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
June 27, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Operations Update
June 16, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Final Results
April 24, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
February 15, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
February 13, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
February 08, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
March 27, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
March 12, 2024
Via
News Direct
Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
March 12, 2024
Via
TheNewswire.com
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million
February 28, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent
February 01, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
January 15, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
November 27, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed
November 15, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
September 18, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed
January 07, 2024
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £534,375
November 28, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - Clinical Hold Lift Plan is accepted by FDA
September 14, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Patent Application Update
September 08, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Full FDA Review for HEMO-CAR-T IND
July 10, 2023
Via
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
July 03, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.